Millendo Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLND research report →
About the company
Millendo Therapeutics, Inc. is an advanced biopharmaceutical firm dedicated to developing innovative therapies for rare hormonal disorders, primarily within the United States. The company's key therapeutic candidates include livoletide, an investigational drug aimed at Prader-Willi syndrome; nevanimibe, an experimental compound designed for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist intended to alleviate vasomotor symptoms (such as hot flashes) in women experiencing menopause.
- CEO
- Julia Owens
- IPO
- 2012
- Employees
- 12
- HQ
- Ann Arbor, MI, US
Price Chart
- Market Cap
- $11.15M
- P/E
- -0.19
- P/S
- 0.00
- P/B
- 14.10
- EV/EBITDA
- 1.57
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -729.89%
- ROIC
- -319.49%
- Revenue
- $0 · 0.00%
- Net Income
- $-26,262,000 · 37.24%
- EPS
- $-6.33 · -322.00%
- Op Income
- $0
- FCF YoY
- 100.00%
- 52W High
- $41.55
- 52W Low
- $1.06
- 50D MA
- $18.86
- 200D MA
- $25.14
- Beta
- 0.48
- Avg Volume
- 140.97K
Get TickerSpark's AI analysis on MLND
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 22, 20 | Nuechterlein Carole | other | 12,000 |
| Jun 22, 20 | HOWE JOHN P MD | other | 12,000 |
| Jun 22, 20 | Gallagher Carol Giltner | other | 12,000 |
| Jun 22, 20 | NICHOL GEOFFREY | other | 12,000 |
| Jun 22, 20 | Hindman James M. | other | 12,000 |
| May 25, 20 | JOSEPH TAMARA L | other | 80,000 |
| May 25, 20 | Arbet-Engels Christophe | other | 80,000 |
| Feb 10, 20 | Arbet-Engels Christophe | other | 140,000 |
| Feb 10, 20 | Arbet-Engels Christophe | other | 0 |
| Jan 31, 20 | JOSEPH TAMARA L | other | 56,250 |
Our MLND coverage
Recent articles, reports, and earnings notes.
No research on MLND yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MLND report →Similar companies
Peers in the same neighborhood.